AstraZeneca na-enweta nkwalite nchịkwa maka ọgwụ oncology

AstraZeneca nwetara nkwalite okpukpu abụọ maka pọtụfoliyo oncology ya na Tuesday, mgbe ndị na-ahụ maka US na European nabatara ntinye iwu maka ọgwụ ya, nzọụkwụ mbụ iji nweta nkwado maka ọgwụ ndị a.

Onye na-emepụta ọgwụ Anglo-Swedish, na MedImmune, ogwe aka mmepe ya gbasara ihe ọmụmụ ihe gbasara ihe ndụ ụwa, mara ọkwa na US Food and Drug Administration (FDA) anabatala akwụkwọ ikike maka moxetumomab pasudotox, ọgwụ ọhụrụ nwere ike ịgwọ ndị ọrịa toro eto nwere cell ntutu. leukemia (HCL) ndị natara opekata mpe ahịrị abụọ gara aga.

FDA enyela ọkwa ọgwụ "nyocha ụzọ", nke enyere ya ọgwụ ndị, ọ bụrụ na akwadoro ya, ga-enye nkwalite dị ukwuu na ọgwụgwọ, nyocha, ma ọ bụ mgbochi nke ọnọdụ dị njọ. A na-atụ anya mkpebi na nkeji nke atọ nke afọ a.

Iche iche, European Medicines Agency nabatara nrubeisi nke Lynparza, ọgwụ nke AstraZeneca nwere ugbu a na mmekorita 50:50 na Merck, ụlọ ọrụ ọgwụ na United States, iji gwọọ ọrịa ara ara na-agbasa n'ebe ọzọ n'ime ahụ maka ndị ọrịa nwere otu. mkpụrụ ndụ ihe nketa.

Ọ bụrụ na akwadoro ya, ọgwụ ahụ ga-abụ onye na-egbochi PARP mbụ maka ọgwụgwọ ọrịa kansa ara na Europe. PARP bụ protein a na-achọta na sel mmadụ nke na-enyere mkpụrụ ndụ ndị ahụ aka ịrụzi onwe ha mgbe ha mebiri emebi. Site n'ịkwụsị usoro nrụzi a na mkpụrụ ndụ kansa, ndị na-egbochi PARP na-enyere mkpụrụ ndụ aka ịnwụ.

Lynparza na Jenụwarị ghọrọ onye mmechi PARP mbụ kwadoro n'ebe ọ bụla n'ụwa maka ọrịa ara ara, mgbe ọ meriri n'ihu n'ihu ndị na-achịkwa US.

N'ime nnwale ọhụrụ a, Lynparza mere ogologo ndụ na-enweghị ọganihu ma e jiri ya tụnyere chemotherapy wee belata ihe ize ndụ nke ọganihu ọrịa ma ọ bụ ọnwụ site na pasent 42.

Na 2017 otu ụzọ n'ụzọ ise nke ahịa ngwaahịa Astra sitere na oncology na ụlọ ọrụ ahụ na-atụ anya na oke a ga-ebili. Oke òkè n'ime otu ahụ mechiri 0.6 pasent na £49.26.

Na mmepe dị iche, Compugen, ụlọ ọrụ na-ahụ maka ọgwụ na Israel, kwuru na ya na MedImmune abanyela na nkwekọrịta ikike pụrụ iche nke ga-eme ka mmepụta nke ngwaahịa mgbochi ọrịa gwọọ ọrịa kansa.

MedImmune nwere ikike ịmepụta ọtụtụ ngwaahịa n'okpuru ikike "ma ga-abụ naanị maka nyocha, mmepe na ọrụ azụmahịa n'okpuru nkwekọrịta", Compugen kwuru.

Ụlọ ọrụ Israel ga-anata ụgwọ $ 10m n'ihu ma tozuo ịnata ihe ruru $ 200m na ​​mmepe, usoro iwu na azụmahịa maka ngwaahịa mbụ, yana ụgwọ eze na ahịa ngwaahịa n'ọdịnihu.

Anat Cohen-Dayag, onye isi ụlọ ọrụ Compugen, kwuru na nkwekọrịta ahụ "na-enye anyị ohere ịnweta ọganihu sayensị kpọmkwem na mmemme anyị, ebe anyị na-aga n'ihu na-akwalite mmemme ndu anyị n'ime ule ụlọ ọgwụ".